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Over the past decade, there has been a progressive evolution of cardiac marker testing in
patients with acute coronary syndromes (ACS). This has not only resulted in a dramatic shift
in how we view the diagnosis of myocardial infarction (MI), but it has also extended the role
of cardiac marker testing into risk stratification and guidance of treatment decisions. By the
year 2000, the development of highly sensitive and cardiac-specific troponin assays had
resulted in a consensus change in the definition of MI, placing increased emphasis on
cardiac-marker testing with troponins as the new gold standard. Furthermore, and perhaps
more importantly, the role of the troponins as superior markers of subsequent cardiac risk in
ACS patients became firmly established. Most recently, the supportive role of these markers
in identifying patients with ACS who may derive particular benefit from potent anti-
thrombotic and anti-platelet therapy or early invasive treatment strategies has been demon-
strated. This paper will review the evolution of these important roles of troponin testing for
risk stratification in ACS. (J Am Coll Cardiol 2003;41:31S–36S) © 2003 by the American
College of Cardiology Foundation
The clinical spectrum of ischemic heart disease is diverse,
ranging from silent ischemia to acute myocardial infarction
(MI). Initial components of assessing a patient with isch-
emic heart disease include the clinical history, physical
examination, 12-lead electrocardiography, and measure-
ment of biochemical markers. The gold standard for diag-
nosis of MI has been an elevated serum level of creatine
kinase-myocardial band (CK-MB), the cardiac-specific iso-
form of CK. This measure satisfied one component of the
diagnostic criteria for MI proposed by the World Health
Organization and was later extended for the MONItoring
trends and determinants in CArdiovascular disease
(MONICA) study (1). However, elevated CK-MB may not
detect all myocardial necrosis. In patients who die suddenly
after severe or silent episodes of ischemia, autopsies fre-
quently reveal micronecrosis that was not reflected in
routine CK-MB measurements (2,3). In addition, myocar-
dial biopsies taken during coronary artery bypass surgery in
patients with unstable angina have shown platelet aggre-
gates in the microvasculature, with associated myocardial
necrosis, but without serum CK-MB elevation (4).
New cardiac markers with superior specificity and sensi-
tivity for myocardial damage and greater ability to risk-
stratify patients with ischemic myocardial necrosis are now
challenging the role of CK-MB. The troponins (T, I, and
C) are subunits of the thin filament-associated troponin-
tropomyosin complex, which is involved in regulating stri-
ated muscle contraction. Monoclonal antibody-based assays
have been developed that are specific for the cardiac iso-
forms of troponin (5,6). Using such assays, data are now
available confirming that troponins can identify myocardial
micronecrosis even when an MI diagnosis has been excluded
according to the conventional definition (7,8).
In response to these and other issues, a new definition of
MI was proposed in September 2000 (9) which emphasizes
the use of cardiac troponins as the preferred marker of
myocardial necrosis in the context of ischemic symptoms in
routine clinical practice. Troponin measurement has also
been included as a fundamental component of diagnosis and
risk stratification in the latest revision of the American
College of Cardiology/American Heart Association guide-
lines for management of non–ST-segment elevation acute
coronary syndromes (NSTE ACS) (10). This review will
describe the data that support the conversion to a “troponin
gold standard.”
TROPONINS FOR
DIAGNOSIS AND RISK STRATIFICATION
Troponins as diagnostic markers. Compared with CK-MB
measurement, troponin assays are substantially more sensi-
tive in the detection of myocardial injury. The release
kinetics of troponins T and I are similar; both are detectable
in the serum within 4 to 12 h after the onset of myocardial
necrosis and depending on the duration of ischemia and
reperfusion status, peak values occur 12 to 48 h from
symptom onset. Therefore, serial sampling, including a
baseline sample and follow-up testing at 8 to 12 h after
symptom onset, is recommended. Although troponin I is
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cleared more quickly than troponin T, both isoforms may
remain elevated in the serum for several days after myocar-
dial injury, allowing for diagnostic confirmation even when
patients delay presentation after symptom onset. Because of
their long serum half-lives, however, neither troponin I nor
troponin T assays are ideal for detection of re-infarction
after an index event.
Troponins as prognostic indicators in NSTE ACS. Tro-
ponin measurement is also a powerful instrument for risk
stratification in patients with acute cardiac ischemia. Pa-
tients with chest pain at rest, but without ST-segment
elevation, are a particularly challenging group for both
diagnosis and risk stratification, even when clinical or
angiographic data are considered (11). Because the extent of
myocardial necrosis is an important prognostic indicator in
this situation (12), early identification of high-risk patients
is as important as confirming a diagnosis of MI. It not only
affects initial triage decisions but also can influence medical
and interventional choices. As early as 1992, the prognostic
value of troponin T was convincingly demonstrated (13).
The rate of major cardiac events during and after hospital-
ization among troponin T–positive patients with Braunwald
class III unstable angina was 15%, compared with only 1.9%
among similar troponin T–negative patients (p  0.003).
Several studies of ischemic patients without ST-segment
elevation have investigated the risk of death or nonfatal MI
at varying intervals after presentation. The FRagmin during
InStability in Coronary artery disease (FRISC) trial inves-
tigators (14) observed a strong correlation between troponin
elevation and 30-day and 5-month mortality. Stubbs et al.
(15) showed a trend toward more frequent death or MI
among troponin T–positive than troponin T–negative pa-
tients during a three-year follow-up (29% vs. 17%, respec-
tively; p  0.07) which reached statistical significance after
adjustment for revascularization (p  0.042). The Throm-
bolysis In Myocardial Infarction (TIMI) IIIB investigators
found an increased risk for 42-day mortality among unstable
angina patients who were troponin I–positive at baseline
(16) which was directly proportional to troponin I elevation.
Among 855 high-risk ACS patients in the Global Utili-
zation of Strategies To open Occluded arteries (GUSTO)-
IIa troponin substudy, baseline troponin T was found to be
a powerful marker of short-term mortality risk (17) and to
be linearly related to increasing troponin T levels across a
wide range of troponin T values. After adjustment for
CK-MB level and electrocardiographic category, baseline
troponin T level remained a strong predictor of 30-day
mortality (chi-squared, 9.2; p  0.027), while CK-MB was
no longer significant. At one year, mortality among tropo-
nin T–positive patients was 14.1% compared with 4.5%
among troponin T–negative patients (p  0.0001) (18).
In a meta-analysis that included data from 4,000
patients in a number of studies, risk ratios for death or MI
for troponin positivity were 2.7 for troponin T (95%
confidence interval [CI], 2.1 to 3.4; p  0.001) and 4.2 for
troponin I (95% CI, 2.7 to 6.4; p  0.001) (19). However,
among individual studies, the odds ratios (ORs) varied
considerably.
A recent meta-analysis that considered variable follow-up
durations has helped to refine estimates of the level of risk
associated with elevated troponins (20). Pooled ORs for
death or MI at 30 days were 2.86 (95% CI, 2.35 to 3.47; p
 0.0001) in patients with ST-segment elevation and 4.93
(95% CI, 3.77 to 6.45; p  0.0001) in patients with NSTE.
This analysis emphasized the ability of troponins to detect
myocardial necrosis in the absence of ST-segment elevation
and to predict heightened risk in both groups of patients.
Isolated troponin elevation across the spectrum of clin-
ical presentations. Using data from the Platelet IIb/IIIa
Antagonism for the Reduction of Acute coronary syndrome
events in a Global Organization Network (PARAGON) B
and GUSTO IIa troponin substudies and the CHest pain
Evaluation by Creatine Kinase-MB, Myoglobin, And Tro-
ponin I (CHECKMATE) studies, Rao et al. (21) investi-
gated the relationship of isolated troponin elevation with
24-h and 30-day clinical events across the spectrum of low-
to high-risk presentations with chest pain. Patients who
were both troponin- and CK-MB-positive had the highest
odds of 24-h and 30-day death or MI, regardless of clinical
presentation. However, isolated troponin positivity carried
higher risk than isolated CK-MB positivity in both high-
and low-risk patients. For patients with isolated troponin
elevation, the unadjusted ORs of death or MI at 24-h were
5.2 (95% CI, 2.3 to 11.9) and 52.4 (95% CI, 17.0 to 161.4)
for high- and low-risk patients, respectively. The adjusted
ORs of 30-day death or MI were 1.3 (95% CI, 0.7 to 2.3)
and 7.5 (95% CI, 2.6 to 21.5) for high- and low-risk
patients. The risks of 24-h and 30-day death or MI were
lower with isolated CK-MB elevation than with isolated
troponin elevation, and they were not significantly greater
than if both markers were negative.
Therapeutic potential for troponin-identified, high risk
patients. Angiographic findings strongly support troponins
as markers of platelet aggregation, thrombus formation, and
distal embolization leading to myonecrosis in ACS patients
with elevated troponins. In the Chimeric c7E3 AntiPlatelet
Therapy in Unstable REfractory angina (CAPTURE) trial
(22), angiograms showed increased visual thrombi in tropo-
nin T–positive patients (11.6% vs. 4.0%; p  0.01). These
patients also had greater thrombus resolution and reduced
clinical outcomes after treatment with abciximab than
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CK-MB  creatine kinase-myocardial band
GP  glycoprotein
LMWH  low-molecular-weight heparin
MI  myocardial infarction
NSTE  non–ST-segment elevation
PCI  percutaneous coronary intervention
RR  relative risk
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troponin T–negative patients, suggesting a selective poten-
tial for enhanced effectiveness of anti-thrombotic and anti-
platelet agents.
Troponin status and treatment benefit from low-
molecular-weight heparins (LMWH). Among 976 pa-
tients in the FRISC trial who were randomized to the
LMWH, dalteparin, or placebo, there was a linear relation-
ship between baseline troponin T level and death or MI in
the follow-up (23). Patients with troponin T levels of either
0.06, 0.06 to 0.18, or 0.18 ng/ml within 24 h of
admission had rates of death or MI of 4.3%, 10.5%, and
16.1%, respectively. Among troponin T–positive patients
only, there was a strong reduction in the rate of death or MI
with dalteparin, from 6.0% to 2.4% (relative risk [RR] 0.41,
95% CI, 0.18 to 0.92), a benefit that persisted at 40 and 150
days.
Among high-risk patients with NSTE ACS and negative
CK-MB measures enrolled in a TIMI 11B substudy, 50.1%
were troponin I–positive (0.1 ng/ml) (24). There was a
strong association between troponin I elevation during the
first 24 h and an adverse clinical outcome at 48 h and 14
days. In this study, treatment with enoxaparin conferred
benefit among troponin I–positive patients, for whom a 47%
reduction (p  0.001) in the composite end point (death,
MI, urgent revascularization) was observed at 14 days. No
benefit was found in troponin I–negative patients.
Troponin status and benefit from platelet glycoprotein
(GP) IIb/IIIa receptor blockade. In the CAPTURE trial,
abciximab reduced MI before, during, and after angioplasty
in patients with refractory unstable angina after documen-
tation of coronary artery lesions amenable to angioplasty
(25). A substudy found that abciximab was more beneficial
in patients with elevated troponin T (0.1 ng/ml) at
baseline (26). The OR for death or nonfatal MI for
abciximab versus placebo was 0.32 in troponin T–positive
patients (95% CI, 0.12 to 0.49; p  0.002) and was driven
primarily by a reduction in the MI component (p  0.001).
No such benefit was observed in troponin T–negative
patients.
In the Platelet Receptor inhibition for Ischemic Syn-
drome Management (PRISM) and Platelet Receptor inhi-
bition for Ischemic Syndrome Management in Patients
Limited by Unstable Signs and symptoms (PRISM-PLUS)
trials, the small-molecule GP IIb/IIIa inhibitor, tirofiban,
was shown to reduce death or nonfatal MI in patients with
NSTE ACS (27,28). In PRISM-PLUS, treatment with a
heparin-plus-tirofiban combination resulted in lower peak
troponin T levels than heparin alone (5.2  8.3 ng/ml vs.
15.5  29.1 ng/ml; p  0.017) (28). As in the CAPTURE
study, a possible correlation between intracoronary throm-
bus and clinical outcome was also demonstrated (29).
Patients with intracoronary thrombus had significantly
higher rates of death or MI than did patients without
thrombus (19% vs. 10%; p  0.001). In a substudy of the
PRISM trial, a preferential treatment benefit was found
with tirofiban among troponin I–positive and troponin
T–positive patients (30). The rate of death or MI was
significantly lower among troponin I–positive patients
treated with tirofiban (4.3%) than those who received
placebo (13%). No treatment benefit was observed in
troponin I–negative patients.
The PARAGON B Troponin T Substudy investigators
recently reported a 42% reduction in death or MI (p 0.02)
with GP IIb/IIIa receptor inhibitor treatment in troponin
T–positive ACS patients (31). The lamifiban treatment
resulted in an event rate approaching that of troponin
T–negative patients (32).
The PARAGON B study, along with the CAPTURE
and PRISM trials, provided strong evidence that the treat-
ment effect of GP IIb/IIIa antagonists is amplified in
troponin-positive patients. As shown in Table 1 (32),
however, these studies differed in several important ways,
preventing their results from being generally applicable in
routine clinical practice (26,30,32,33). For example, in the
CAPTURE trial, only patients with documented coronary
artery disease who failed medical therapy and were sched-
uled for percutaneous coronary intervention (PCI) were
enrolled. This limits its extrapolation to current clinical








PRISM (30) 2222 Retrospective ACS 3.5% 13.7% 74%
CAPTURE (26,33) 1265 Retrospective ACS  PCI 5.8% 19.6% 70%
PARAGON-B (32) 1160 Prospective ACS 11.0% 19.0% 42%
PRISM-PLUS* 110 Retrospective ACS 3.6% 20.6% 71%
GUSTO IV ACS† 7707 Prospective ACS 10.5% 10.7% —
*Januzzi JL, personal communication. February 21, 2001. †The GUSTO IV ACS Investigators; Presented at the XXII Congress
of the European Society of Cardiology, August 2000. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein
IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B Troponin T
Substudy. Circulation 2001;103:2891–96.
ACS  acute coronary syndromes; CAPTURE  Chimeric c7E3 AntiPlatelet Therapy in Unstable REfractory angina;
GUSTO  Global Utilization of Strategies To open Occluded arteries; MI  myocardial infarction; PARAGON  Platelet
IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI 
percutaneous coronary intervention; PRISM-PLUS  Platelet Receptor inhibition for Ischemic Syndrome Management in
Patients Limited by Unstable Signs and symptoms.
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practice. In the PRISM study, tirofiban was used without
concomitant heparin and was not continued for PCI.
Further, the troponin substudies were initiated after the
CAPTURE and PRISM main trials were completed
(26,30), while the PARAGON B substudy was carried out
concurrently with the main trial (32). Nevertheless, the
findings in the PARAGON B study were similar to those
described by previous investigators. Although the subgroup
comparison was not statistically rigorous, results were also
similar in medically- and interventionally-treated patients in
both PRISM and PARAGON B (30,32).
We previously (32) performed a meta-analysis of the
PRISM, CAPTURE, and PARAGON B troponin sub-
study data to better define the interaction of troponin status
with treatment on the end point of death or MI. As shown
in Figure 1, none of these studies revealed a treatment effect
with a GP IIb/IIIa antagonist in troponin-negative patients.
However, among troponin-positive patients, there was a
significant treatment effect (pooled OR, 0.34; 95% CI, 0.19
to 0.58). Further, for the three studies combined, the pooled
OR for interaction of treatment by troponin status was
highly significant (OR, 0.33; 95% CI, 0.19 to 0.57). As in
the studies of LMWHs, these findings suggest that the
benefit of GP IIb/IIIa inhibitors is enhanced by troponin-
positive status across a spectrum of treatment indications
and use patterns.
These studies illustrate how a biochemical risk marker
may be used to improve outcomes by guiding decisions to
optimize anti-thrombotic therapy. However, the results of
the GUSTO IV ACS trial raised questions about the
particular benefit of GP IIb/IIIa blockers in patients with
ACS and elevated troponin levels (34). Unlike previous
studies of GP IIb/IIIa inhibitors in NSTE ACS, GUSTO
IV failed to show a benefit of abciximab over placebo in
either medically-managed NSTE patients overall or in
troponin T–positive patients. This is particularly notewor-
thy, considering that the relationship of troponin elevation
to risk was similar to the relationship found in previous
studies. Although patients were not managed with early
cardiac catheterization/intervention, it is unlikely that this
factor alone accounts for the findings, because other studies
showed benefits from GP IIb/IIIa blockade in patients who
did not undergo revascularization.
Troponin status and benefit from early angiogra-
phy. The benefit of an early choice of angiography based on
troponin status has also been investigated. In the TIMI-
IIIB trial, the RR for 42-day mortality among patients with
troponin I levels 0.4 ng/ml, compared with troponin
I–negative patients, was 1.11 (95% CI, 1.05 to 1.17; p 
0.016) (35). However, in the subgroup of troponin I–posi-
tive patients randomly assigned to the invasive strategy,
mortality was similar to that of troponin I–negative patients
(RR, 0.92; 95% CI, 0.86 to 0.98; p  0.024) (35). Data
from the GUSTO-IIa substudy also suggested that the
treatment benefit from an early invasive strategy may be
enhanced in troponin-positive patients (36). In this blinded
study, troponin T–positive patients who underwent revas-
cularization had one-year mortality similar to that of tro-
ponin T–negative patients (6.3% vs. 6.2%; p  0.78) (36).
However, one-year mortality among troponin T–positive
patients who did not receive angioplasty was substantially
higher than mortality in troponin T–negative patients (37%
vs. 11%, p  0.001).
The suggestion that early revascularization may result in
improved outcomes was recently confirmed in both the
FRISC II study and the TACTICS trials (37,38). A
substudy of FRISC-II addressed the influence of troponin
T elevation and ST-segment depression on the effects of an
early invasive versus noninvasive strategy (39). Among
troponin T–positive patients, there was a 29.7% reduction
in the incidence of death or MI at one-year (RR 0.70, 95%
CI, 0.55 to 0.90; p  0.005). A similar effect was observed
for troponin T elevation in combination with ST-segment
depression at entry.
CONCLUSIONS
Measurement of cardiac troponins is rapidly assuming the
position of gold standard for the biochemical diagnosis of
myocardial necrosis, replacing conventional CK-MB mea-
surement. The superiority of troponin T and I measurement
in the diagnosis of myocardial damage, which may represent
even microscopic zones of myocardial necrosis, has been
clearly demonstrated in numerous studies over the past
decade. The recently proposed new definition of MI (9)
identifies cardiac troponin (T or I) as the preferred biomar-
ker for routine MI diagnosis. However, retrospective con-
Figure 1. Odds ratios with 95% confidence interval for death or myocardial
infarction among troponin-negative and troponin-positive patients and for
interaction of troponin status with treatment effect for Platelet Receptor
inhibition for Ischemic Syndrome Management (PRISM), Chimeric c7E3
AntiPlatelet Therapy in Unstable REfractory angina (CAPTURE), Plate-
let IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome
events in a Global Organization Network (PARAGON-B), and combined
trials. Values to the left of 1.0 indicate a benefit of glycoprotein IIb/IIIa
inhibition. TnT troponin T. Newby LK, Ohman EM, Christenson RH,
et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute
coronary syndromes and troponin T-positive status: the PARAGON-B
Troponin T Substudy. Circulation 2001;103:2891–6. Reproduced with
permission from Lippincott, Williams and Wilkins.
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firmation of MI is only one function of a cardiac marker. A
role in risk stratification and in therapeutic choices, such as
the use of LMWHs, GP IIb/IIIa inhibitors, and coronary
revascularization in accordance with treatment guidelines, is
also crucially important. In this respect as well, troponin
measurement has clearly demonstrated superiority over
CK-MB in its usefulness as a complement to other routine
assessments, including the history and electrocardiogram.
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